Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

IceCure announced it concluded a meeting with the FDA's Center for Devices and Radiological Health regarding the Company's De Novo marketing authorization request for ProSense® in the treatment ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

The drug's use expanded into the first-line setting in combination with endocrine therapy in 2020, and the following year it also got a green light as adjuvant (pre-surgery) treatment alongside ...

Although there is no certainty that vaginal oestrogen carries no increased risk for breast cancer patients, up to 20% either stop or consider stopping their adjuvant endocrine therapy because it ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...